FDA approves wider range of treatments for cancer drug

A drug previously approved to treat different skin cancers recently got a Food and Drug Administration greenlight to treat a few more.

Dr. Davor Vugrin, a hematologist and oncologist in Lubbock, said Keytruda already proved to be effective against several skin cancers. The FDA’s approval now includes treatment for types of colorectal cancer, gastrointestinal cancer, breast cancer, prostate cancer, bladder cancer, thyroid cancer and more.


The FDA granted an accelerated approval of Keytruda in May to treat tumors that originate from specific genetic biomarkers.


A press release from the FDA says about 39.6 percent of the 149 patients who participated in clinical trials for Keytruda showed a complete or partial tumor shrinkage. The response lasted for six months or more for about 78 percent of those patients, according to the press release.


“It’s quite an exciting drug,” Vugrin said.


Cancer treatment drugs have traditionally been approved by the FDA based on their location on the body, Vugrin said. This is the first time a drug has received FDA approval based on a genetic feature.


Dr. Patrick Reynolds, professor and director of the cancer center for the Texas Tech’s Health Sciences Center, said the accelerated approval means responses in the clinical trials were favorable.


It’s not unusual for drugs to be placed in the accelerated approval track, he said. Keytruda is unique.


It works by targeting the root of a genetic-based cancer and blocks T cells in the body from allowing it to replicate, he said.


T cells are an essential part of the immune system, Reynolds said.


“T cells are the immune cells in our body that recognize cells that are not supposed to be there,” he said. “If you transplant tissue from somebody else in you, that’s what’s going to reject it.”


When a mutation slips into a DNA strand, it often leads to cancer, he said.


“When we get mutations, you don’t usually get Wolverine or X-Men,” Reynolds said. “You get cancer.”


That’s why T cells are important in controlling cancers, he said.


Vugrin said Keytruda targets the T cells and makes them aware of the cancer and blocks them from aiding in the production of more cancer cells.


“The basic mechanism of how it works is by sort of helping the immune system to fight the cancer cell,” Vugrin said.


Keytruda has been effective in treating skin cancers like melanoma, he said. It’s also been approved to treat lung cancers and colorectal cancers.

Related Stories

TTUHSC’s Graduate School of Biomedical Sciences Hosts Student Research Week

The Texas Tech University Health Sciences Center (TTUHSC) Graduate School of Biomedical Sciences hosted its 34th Annual Student Research Week March 8-11.

TTUHSC Researcher Receives NIH Grant to Study Vulnerabilities in Specific Cancer Types

The National Cancer Institute awarded a five-year, $1.9 million grant to C. Patrick Reynolds, M.D., Ph.D., director for the School of Medicine Cancer Center at TTUHSC.

The Hype Around Artificial Intelligence

Richard Greenhill, DHA, FISQua, FACHE, discusses the hype and reality surrounding AI in healthcare.

Recent Stories


Living with Dysphagia

Dysphagia is a swallowing disorder that affects a person’s ability to eat or drink, affecting between 300,000 and 700,000 people in the United States each year.


Equip Yourself with Lifesaving Skills – Know How to Stop the Bleed During National Stop the Bleed Month

Brittany Bankhead, M.D., an assistant professor of surgery for the Division of Trauma, Burns and Critical Care at the Texas Tech University Health Sciences Center, said life-threatening bleeding can happen in everyday scenarios.


TTUHSC Celebrates Completion of Physician Assistant Building Expansion

TTUHSC celebrated the completion of the School of Health Professions Physician Assistant Program expansion May 16 with a ceremonial ribbon cutting.